| ORGANIZATION'S MISSION |
FORM 990, PART III, LINE 1 JDRFs mission is to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications. JDRF is the leading global organization focused on T1D research and is committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until a cure is found. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF works every day to change the reality of this life-threatening autoimmune disease for millions of people - and to prevent anyone else from contracting the disease - by funding research, advocating for government support of research and new therapies, ensuring new therapies and technologies come to market, and connecting and engaging the T1D community. JDRF has funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease. JDRF has played a role in nearly every T1D therapeutic advance of the past four decades, including the FDA-approved hybrid closed-loop artificial pancreas system in September 2016. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($75,084,432) RESEARCH FUNDING JDRF funds research with the greatest potential to cure, prevent and treat type 1 diabetes (T1D). Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF has committed more than $2 billion to this research since 1970. The full impact of JDRFs research investment extends well beyond direct funding. JDRF leverages partnerships with academia, industry and clinicians to ensure that the most promising research opportunities are funded and accelerated. JDRF often provides early stage funding to research projects, and the results of those projects often lead to follow-on participation from many other entities--both other non-for-profit funders and corporations. JDRF's research team is staffed by accomplished experts and leaders in the field of T1D science and medicine who guide the organization's funding efforts every step of the way. JDRFs highest priority remains funding research to deliver a cure for T1D and its complications. At the same time, JDRF is focused on developing better treatments that will transform the way people with T1D treat the disease today to help them live healthier lives now and in the future. The foundation's diversified research portfolio includes the following therapy areas: Artificial Pancreas: Artificial pancreas systems use technology to replicate the operation of a normal human pancreas and are one of the most revolutionary advances in diabetes care since the discovery of insulin. These systems link continuous glucose monitors and insulin pumps to smart software so that the right amount of insulin is delivered at the right time. Glucose Control: Glucose-responsive insulins(GRIs)--or smart insulins--promise to be a game-changer in blood-sugar management. GRIs will be the first-ever insulin formulation that turns on and off in response to blood sugar highs and lows. JDRF is also funding research that explores the benefits of combining novel or repurposed drugs with standard insulin therapy. Beta Cell Replacement: This therapy, also known as encapsulation, can be implanted to provide long-term relief from insulin dosing without the need for immune suppression. JDRF-supported scientists are improving biomaterials for encapsulation devices to protect implanted beta cells from autoimmune attack, among other strategies. Beta Cell Restoration: This drug or biologic-based therapy represents a full biological cure for people with T1D. It stimulates restoration of the bodys own beta cells and the capacity to produce insulin. We are repurposing drugs that may reduce beta cell stress and/or induce survival, as well as funding immune therapies that will stop the disease in its tracks. Complications: JDRF-funded research has already yielded new treatments for diabetic eye and kidney disease, the most common complications. Today, researchers are identifying biomarkers and accelerating the completion of clinical trials of potential treatments. Prevention: JDRF research has identified a number of potential triggers, including viruses and environmental conditions, which could open the door to new vaccines and other prevention strategies. The organization is also funding efforts to stall the progression of the disease in those at risk or newly diagnosed. For more information, visit jdrf.org/research. LINE 4B ($21,188,795) RESEARCH CONSORTIA JDRF maintains an in-house team of skilled scientific, policy and government relations professionals with credentials, including PhD.'s, MD's, MBAs, MAs, and others, each of whom plays a critical role in leading and supporting the research strategy and the disbursement of research funds from JDRF and others to create a world without type 1 diabetes (T1D). In their respective responsibilities, these professionals perform the functions of identifying, evaluating and influencing groundbreaking research being funded by JDRF, other foundations, governments and industry to achieve the organization's mission. These professionals also work with regulatory and policy officials to ensure research can proceed without delay and that research results are well understood by healthcare decision makers. As part of these efforts, JDRF organizes and funds scientific meetings, symposia, and conferences with the purpose of reviewing research proposals, ensuring that JDRF's research strategy is well aligned with the needs of the T1D community and allowing JDRF to provide scientific updates on the research it manages. JDRF also works with its external Research Advisory Committee (RAC), which is composed of professionals who are internationally renowned for their expertise in research as well as the care and treatment of those with T1D. The RAC advises on matters of policy pertaining to research philosophy and procedures to help the organization be most effective. All of this work to convene the best minds in the field enhances JDRF's ability to forecast future scientific direction, to judge the potential efficiency and effectiveness of new pathways and to identify gaps where JDRF can focus its funding to make the most impact. It is from this position of strength that JDRF identified opportunities where the Foundation can make significant advances in the near future and launched a five-year strategic plan in 2015 to accelerate progress to cure, prevent and treat T1D and its complications LINE 4C ($52,293,201) PUBLIC EDUCATION Because of its leading role in type 1 diabetes (T1D) research globally, JDRF is in a unique position to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people with the disease and their families and the general public, but also those at risk for developing the disease. Type 1 diabetes strikes both children and adults suddenly, and the adjustment period following a diagnosis can be overwhelming. JDRF educates people about the warning signs of T1D, which can be profoundly helpful in ensuring timely diagnoses and reducing the potential, short-term, catastrophic consequences of T1D. The foundation provides outreach services and resources, like the JDRF Bag of Hope and the JDRF Adult T1D Care Kit, for newly diagnosed children and adults, respectively, and toolkits for managing all ages and stages of life with T1D. JDRF also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through JDRF's Clinical Trials Connection matching tool: www.jdrf.org/research/clinical-trials). Through all of its U.S. chapters and online, JDRF supports the T1D communitys diverse needs, connecting people with local support, expert resources and the worldwide effort to end this serious disease. |
| CONFLICT OF INTEREST POLICY |
FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote. |
| PUBLIC DOCUMENTS |
FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials |
| EXECUTIVE COMPENSATION POLICY |
PART VI, SECTION B, LINES 15a & 15b JDRFs Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Executive Committee. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundations talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRFs key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by the Compensation Committee, and the basis for their determination are documented contemporaneously in the minutes of the Committees meetings, including most recently on December 4, 2015. |
| 990 REVIEW PROCESS FORM 990 |
SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Tax Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRFs Chief Financial Officer and Director of Accounting and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRFs Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRFs Board of Directors for review and comment before it is filed with the Internal Revenue Service. |
| UPDATED BYLAWS, FORM 990,PART VI, PAGE 6, QUESTION 4 |
ON APRIL 14, 2016 JDRF AMENDED AND MADE SIGNIFICANT CHANGES TO ITS BYLAWS. CHANGES THAT WERE MADE INCLUDE PROVISIONS ON FORMATION AND CLOSING OF CHAPTERS; AND UPDATED TERM LIMITS OF BOARD MEMBERS, OFFICERS, CHANCELLORS, AND COMMITTEE MEMBERS. THE BYLAW AMENDMENTS ALSO REDEFINE JDRF BOARD COMMITTEES AND THEIR RESPONSIBILITIES. |
Attach to Form 990 or 990-EZ.